AI-generated analysis. Always verify with the original filing.
Radiopharm Theranostics Limited reported a half-year loss of $28,243,811 for the period ended 31 December 2025, up from $19,643,011 prior year, due to increased R&D expenditures, alongside net assets of $49,940,027 and cash of $34,515,397 boosted by a $35 million placement. The company advanced multiple radiopharmaceutical clinical programs and increased ownership in Radiopharm Ventures, LLC to 87.5%.
Event Type
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Loss from ordinary activities after tax attributable to owners | $-27.0M | |
| Loss for the half-year attributable to owners | $-28.2M |
Mr Bruce Goodwin
Effective: 2025-11-19
N/A
Mr Phillip Hains
Effective: 2025 AGM
N/A
Dr Leila Alland
Effective: 2025 AGM
N/A
Dr Oliver Sartor
Effective: during half-year
N/A